The purpose of Idorsia is to discover, develop, and commercialize innovative medicines to help more patients. We have more ideas, we see more opportunities, and we want to transform the horizon of therapeutic options. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options. See our LinkedIn community guidelines: https://bit.ly/4nAfOZp Idorsia privacy policy: https://www.idorsia.com/legal/privacy-policy
Looking for a particular Idorsia Pharmaceuticals Ltd employee's phone or email?
The Idorsia Pharmaceuticals Ltd annual revenue was $35.1 million in 2026.
Christopher Kohl is the Vice President, Head of Non-clinical Development of Idorsia Pharmaceuticals Ltd.
712 people are employed at Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd is based in Allschwil, Basel Landschaft.
The NAICS codes for Idorsia Pharmaceuticals Ltd are [3254, 325, 32541, 32].
The SIC codes for Idorsia Pharmaceuticals Ltd are [283, 28].